Loading…
Loading…
LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). "This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma.
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase LUND, Sweden, July 1, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and SERB S.A. ("SERB") today announced required regulatory approvals have been obtained and that the previously announced exclusive licensing transaction with SERB has closed.
Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript
The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission to EMA for conversion to full marketing authorization planned for Q4 2026 LUND, Sweden, May 27, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival[*] and patient survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with Idefirix (imlifidase). Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "These positive results represent a significant milestone for Idefirix and for Hansa.
LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. The presentation will include detailed 12-month results from the ConfIdeS trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results.
No recent filings indexed.